On Tuesday, Target Corporation (NYSE:TGT)’s shares declined -0.58% to $81.63.
CVS Health Corporation (CVS) and Target Corporation (TGT) declared that they have reached a definitive agreement for CVS Health to acquire Target’s pharmacy and clinic businesses for about $1.9 billion. Through this agreement, CVS Health will acquire Target’s more than 1,660 pharmacies across 47 states and operate them through a store-within-a-store format, branded as CVS/pharmacy. In addition, a CVS/pharmacy will be comprised of in all new Target stores that offer pharmacy services. Target’s nearly 80 clinic locations will be rebranded as MinuteClinic, and CVS Health will open up to 20 new clinics in Target stores within three years of the close of the transaction. The new clinics will be part of CVS/minuteclinic’s plan to operate 1,500 clinics by 2017. In addition, CVS Health and Target plan to develop five to 10 small, flexible format stores over a two-year period following the deal close, which will each be branded as TargetExpress and comprise a CVS/pharmacy.
Target Corporation operates as a general merchandise retailer in the United States and Canada. It offers household essentials, counting pharmacy, beauty, personal care, baby care, cleaning, and paper products; music, movies, books, computer software, sporting goods, and toys; electronics, such as video game hardware and software; and apparel for women, men, boys, girls, toddlers, infants, and newborns, in addition to intimate apparel, jewelry, accessories, and shoes.
Opko Health Inc. (NYSE:OPK)’s shares gained 3.87% to $16.09.
Opko Health Inc. (OPK) may fit the first condition of being at or near its highs, but it does not fulfill the second. Those short Opko don’t seem to mind all that much, being that 44.92M shares are presently held short, constituting 67% of the float. That’s about a million more shares than last month, representing over $15M in capital spent on shorting the stock in one month, at least.
While shorting itself may tend to discourage some retail investors from taking a position, institutional investors in addition to company insiders are usually astute enough to know that for every short seller, there is a buyer of those shares on the other side. Close to 70% of Opko’s float is held by either insiders or institutions, and it is doubtful that any of those shares will be put on the open market any time soon. And even if some are, the company’s founder and CEO, Dr. Phillip Frost, is picking shares at the same pace that shortsellers are borrowing them to sell.
OPKO Health, Inc., a biopharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies in the United States and internationally. It operates through two segments, Pharmaceuticals and Diagnostics. The company develops various solutions to diagnose, treat, and prevent various conditions, counting point-of-care tests, molecular diagnostics tests, laboratory developed tests, and proprietary pharmaceuticals and vaccines. Its products comprise 4Kscore test that measures the blood plasma levels of four different prostate-derived kallikrein proteins.
At the end of Tuesday’s trade, CNH Industrial NV(BIT:CNHI)‘s shares dipped -0.12% to $8.18.
Carlo Lambro, a member of CNH Industrial’s Group Executive Council and Brand President of Company brand New Holland Agriculture, spoke at a conference held by the World Farmers Organisation (WFO) on June 26 at Expo Milano 2015. The organisation represents an International Organisation of “Farmers for Farmers,” which aims to bring all national producers and farm cooperative organisations together with the objective of developing policies which favour and support farmers’ causes in developed and developing countries around the world. WFO’s work covers all agriculture related thematic areas, with an eye to sustainability and efficiency, placing emphasis on the importance of developing agricultural mechanisation to feed the planet’s growing population.
Carlo Lambro was invited by WFO President Evelyn Ngukela to illustrate the strategies of CNH Industrial and its brand New Holland Agriculture for the future of agriculture and how they plan to address issues regarding the availability of food for the Earth’s population which is predictable to grow to nine billion by 2050.
In terms of the role of private companies in the fight to overcome these challenges, Lambro underlined the dual approach adopted by New Holland. This sees the expansion of mechanised agricultural operations by studying solutions and specific machines for local requirements, especially in developing countries. He also spoke about maximising the efficiencies and productivity of farmland in maturing markets.
Carlo Lambro also explained New Holland’s Clean Energy Leader™ strategy which the brand first began promoting in 2006. He made specific note of the Energy Independent Farm project which is formed upon the idea that if a farm is able to create its own energy sources for operating its agricultural equipment, it will effectively free itself from the constraints of fossil fuels.
CNH Industrial N.V. designs, produces, markets, sells, and finances agricultural and construction equipment, trucks, commercial vehicles, buses, and specialty vehicles, engines, transmissions, and axles worldwide. The Agricultural Equipment segment provides farm machinery and implements, counting two-wheel and four-wheel drive tractors, crawler tractors, combines, cotton pickers, grape and sugar cane harvesters, hay and forage equipment, planting and seeding equipment, soil preparation and cultivation implements, and material handling equipment. This segment offers its products under the New Holland Agriculture, Case IH Agriculture, Steyr, and Miller brand names.
Royal Dutch Shell plc (ADR) (NYSE:RDS.B), ended its Tuesday’s trading session with -1.22% loss, and closed at $57035.
Royal Dutch Shell plc’s (RBS.A) capital comprises of 3,918,015,024 A shares and 2,440,410,614 B shares, each with equal voting rights. Royal Dutch Shell plc holds no ordinary shares in Treasury.
The total number of A shares and B shares in issue is 6,358,425,638 and this figure may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, Royal Dutch Shell plc under the FSA’s Disclosure and Transparency Rules.
Note: This declarement is made following Disclosure and Transparency Rule 5.6.1 and as such the above figures comprise shares purchased by Royal Dutch Shell plc as part of its share buy-back program but not yet cancelled.
Royal Dutch Shell plc operates as an independent oil and gas company worldwide. It operates through Upstream and Downstream segments. The company explores for and extracts crude oil, natural gas, and natural gas liquids. It also converts natural gas to liquids to provide fuels and other products; markets and trades natural gas; extracts bitumen from mined oil sands and converts it to synthetic crude oil; and generates electricity from wind energy. In addition, the company engages in manufacturing, supplying, and shipping crude oil; selling fuels, lubricants, bitumen, and liquefied petroleum gas (LPG) for home, transport, and industrial use; converting crude oil into a range of refined products, counting gasoline, diesel, heating oil, aviation fuel, marine fuel, lubricants, bitumen, sulphur, and LPG; producing and marketing petrochemicals, such as the raw materials for plastics, coatings, and detergents for industrial customers; and alternative energy business. Further, it trades hydrocarbons and other energy-related products; provides shipping services; and produces base chemicals comprising ethylene, propylene, and aromatics, in addition to intermediate chemicals, such as styrene monomer, propylene oxide, solvents, detergent alcohols, ethylene oxide, and ethylene glycol.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
